Boise State University ScholarWorks

College of Health Sciences Presentations

2015 Undergraduate Research and Scholarship Conference

4-20-2015

The Relationship Between E-Cigarette Use and Quit Rates in Public Health Tobacco Cessation Programs

Sophia Brasil

The Relationship Between E-Cigarette Use and Quit Rates in Public Health Tobacco Cessation Programs

Abstract

E-cigarette use is an emerging and fast-growing trend particularly among young people that has not been thoroughly researched in terms of quit rates. Previous research shows that people perceive e-cigarettes to be a safer alternative to assisting tobacco cessation, yet solid result supporting this claim have yet to be published. This research compiled in Fiscal Year 2015 analyzes quantitative evaluation data gathered from state-wide public health tobacco cessation programs in the Northwest. Understanding quit rates related to electronic cigarette use is important to implementing changes in clean indoor air policies, improving quit and abstinence rates in tobacco cessation programs, and advancing accurate perceptions on the safety of e-cigarettes use for all users.

Keywords

quit rate, e-cigarettes, abstinence rates, cessation rates

Disciplines

Public Health Education and Promotion



The Relationship Between E-cigarette Use and Cessation **Rates in Public Health Tobacco Cessation Programs**

Research Question

Is there an association between e-cigarette use and the quit¹ and abstinence² rates of tobacco cessation program participants?

. Quit: stopped using tobacco by the end of the program 2. Abstinence: refrained from tobacco relapse at 1 month follow-up

Purpose

This research aims to provide an opportunity for the public health districts to make informed changes related to the effectiveness of their tobacco cessation programs. The targeted objective is to decrease frequency of tobacco use and increase tobacco abstinence rates of the participants in these programs.

TABLE 1 Hazard quotients associated with the direct exposures of e-cigarette users and the indirect (passive) exposure of non-users

CHEMICAL	Exposure Criteria		Direct Exposure		Indirect Exposure	
	NSRL (ug/day)	CREL (ug/m3)	HQ ¹ NSRL	HQ ¹ CREL	HQ NSRL	HQ CREL
Acetaldehyde	90	140	0.18	0.01	0.004	0.0001
Acrolein	N/A	0.35	N/A	7.0	N/A	0.17
Formaldehyde	40	9	1.64	0.36	0.04	0.009
Cadmium	0.05	0.02	5.13	0.64	0.12	0.015
Lead	0.5	0.15	1.33	0.22	0.03	0.005
Nickel	0.8	0.05	0.42	0.34	0.008	0.007
Nicotine	N/A	5	N/A	222	N/A	5.4
NNK ²	0.014	N/A	2.36	N/A	0.05	N/A
Propylene						
Glycol	N/A	50	N/A	967	N/A	23
¹ Hazard quotients expressed as the ratio of the calculated exposure to the NSRL and CREL health						

Hazard quotients expressed as the ratio of the calculated exposure to the NSRL and CREL health exposure guidelines, with values above 1.0 **bolded.**

²NNK, 4-(nitrosomethylamino)-1-(3-pyridyl)1-butanone).

Table 1

E-cigarettes on average contain higher quantities of chemical than is recommended by the cancer and non-cancer exposure hazard analyses guidelines. They therefore have the potential to present adverse outcomes in user health. Adapted from: Offerman F. J. (2014). The Hazards of E-Cigarettes. ASHRAE Journal, 56(6), 38-44.

Sophia Brasil

Center for Health Policy

Faculty Mentors: Dr. Janet Reis, Lisa MacKenzie

Methods

abstinence rates of each target group.




TABLE 2	Comparison of sample toxicants emitted by
	cigarettes and e-cigarettes

Toxic compound Cigarette (ug in mainstream smoke) (ug per 15 puffs*) (conventional) Formaldehyde 1.6-52 0.20-5.61 9 Acetaldehyde 52-140 0.11-1.36 45 Acrolein 2.4-62 0.07-4.19 1 Toluene 8.3-70 0.02-0.63 12 NNN** 0.005-0.19 0.00008-0.00043 38 NNK** 0.012-0.11 0.00011-0.00283 4								
Acetaldehyde 52-140 0.11-1.36 45 Acrolein 2.4-62 0.07-4.19 1 Toluene 8.3-70 0.02-0.63 12 NNN** 0.005-0.19 0.00008-0.00043 38 NNK** 0.012-0.11 0.00011-0.00283 44	Toxic compound	cigarette	U	Averag (conventional v				
Acrolein 2.4-62 0.07-4.19 1 Toluene 8.3-70 0.02-0.63 12 NNN** 0.005-0.19 0.00008-0.00043 38 NNK** 0.012-0.11 0.00011-0.00283 4	Formaldehyde	1.6-52	0.20-5.61	9				
Toluene 8.3-70 0.02-0.63 12 NNN** 0.005-0.19 0.00008-0.00043 38 NNK** 0.012-0.11 0.00011-0.00283 4	Acetaldehyde	52-140	0.11-1.36	45				
NNN** 0.0005-0.19 0.0008-0.0043 38 NNK** 0.012-0.11 0.00011-0.00283 4	Acrolein	2.4-62	0.07-4.19	15				
NNK** 0.012-0.11 0.00011-0.00283 4 *The authors assumed smokers of e-cigarettes would take an average of 15 puffs per vaping session, corresponding to smolente. 5	Toluene	8.3-70	0.02-0.63	12				
*The authors assumed smokers of e-cigarettes would take an average of 15 puffs per vaping session, corresponding to sm tobacco cigarette.	NNN**	0.005-0.19	0.00008-0.00043	38				
Illtobacco cigarette.	NNK**	0.012-0.11	0.00011-0.00283	4(
**Tobacco-specific nitrosamine, a carcinogenic compound that originates in the curing and processing of tobacoo.	*The authors assumed smokers of e-cigarettes would take an average of 15 puffs per vaping session, corresponding to sm III tobacco cigarette.							

Table 2

In comparison to traditional tobacco cigarettes, e-cigs contain much smaller amounts of these chemicals and are far less toxic. E-cigarettes may provide tobacco users with an alternative that presents less dangerous consequences. Adapted from: Arnold, C. (2014). Vaping and Health: What Do We Know about E-Cigarettes?. Environmental Health Perspectives, 122(9), A244-A249.




ge ratio vs e-cigarette)

- noking one

Expected Results

I expect to see a significant difference in the quit and abstinence rates of smokers who use e-cigarettes compared with smokers who did not use e-cigarettes. anticipate there will be a significant association between e-cigarette use and cessation rates.



Importance of Research

Understanding behaviors in electronic cigarette use is important to implementing changes in clean indoor air policies, improving quit and abstinence rates in tobacco cessation programs, and advancing accurate perceptions on the safety of e-cigarette use for all users.

Acknowledgements

McNair Scholars Program

Center for Health Policy

- Dr. Janet Reis, PhD, Senior Researcher
- Dr. Ed Baker, PhD, Director
- Lisa MacKenzie, MHS, Research Associate

